Alcon to Launch Clareon IOL at ESCRS Meeting

October 6, 2017: By Joan McKenna

alcon-large-3x2Alcon will introduce its new Clareon intraocular lens (IOL) at the 2017 meeting of the European Society of Cataract and Refractive Surgeons, set for Oct. 7-11 in Lisbon, Portugal.

The company describes the Clareon as having the most advanced optic IOL material available. The lens is offered in an automated, disposable, preloaded delivery system.

Alcon, the Texas-based eye care division of Novartis, says it will provide an extensive scientific and educational program at the meeting, with 18 accepted abstracts and more than 10 satellite events.

“We are proud to deliver on our commitment to bring innovations to the surgical community, and Clareon is one of the biggest breakthroughs in the IOL space,” said Mike Ball, chief executive officer of Alcon. “This is a great year for Alcon as we celebrate many important milestones.”

Among those is the 100 millionth implantation of Alcon’s flagship AcrySof lens, Ball said.

Presentations also will include new efficacy and safety data for Alcon’s CyPass Micro-Stent in patients with glaucoma.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

US FDA Approves Icon Bioscience’s DEXYCU for Post-Cataract Surgery Inflammation

FDA’s Gottlieb Appears to Soften Stance on Compounding for Office Use

Genentech’s RG7716 Outperformed Ranibizumab in Phase II Study in Diabetic Macular Edema

Santen Reports Promising Data in Phase I/II Study in Refractory Wet AMD

Q Biomed Signs Agreement with Washington University for Novel Biomarker for Monitoring Glaucoma

pSivida’s Durasert for Posterior Segment Uveitis Yields Positive 12-Month Results in Second Phase III Study

Foundation Fighting Blindness Provides $7.5 Million to Help Develop ProQR’s Candidate for Usher Syndrome

Presbia Names Casey Lind as Chief Operating Officer, Magda Michna, MD, PhD, as Chief Clinical Officer

Astellas Acquires Universal Cells

Pixium Vision Completes Two Successful PRIMA Implantations in Atrophic Dry AMD Patients

Omeros Loses Pass-through Status for Omidria

USC Donations Drop $100 Million after Puliafito Scandal, Report Says

Regeneron’s US Eylea Sales Increase 14 Percent in Q4-2017

Allergan’s Net Sales Climb 12 Percent in Q4-2017; Restasis Sales Grow Nearly 1 Percent

Lucentis’ US Sales Drop 11 percent in Q4-2017, Grow 1 Percent for Full 2017

EyeGate’s EGP-437 for Post-Cataract Pain, Inflammation Produces Mixed Results in Phase IIb Trial

Second Sight Reports Record Number of Argus II Implants in Q4-2017, First Orion Implant in Human

Allergan Appoints Matthew Walsh as CFO

Ocunova Secures $500 Thousand From Two Firms to Pursue Dry Eye Treatment for Diabetic Patients

ReVision Optics Closes Doors; Raindrop Corneal Inlay No Longer Available

Coming soon

2018 Retinal Surgical Devices Report: A Global Market Analysis for 2017 to 2023